JP7233720B2 - ヒトメソセリンを特異的に認識する細胞表面分子、il-7、及びccl19を発現する免疫担当細胞 - Google Patents

ヒトメソセリンを特異的に認識する細胞表面分子、il-7、及びccl19を発現する免疫担当細胞 Download PDF

Info

Publication number
JP7233720B2
JP7233720B2 JP2019560545A JP2019560545A JP7233720B2 JP 7233720 B2 JP7233720 B2 JP 7233720B2 JP 2019560545 A JP2019560545 A JP 2019560545A JP 2019560545 A JP2019560545 A JP 2019560545A JP 7233720 B2 JP7233720 B2 JP 7233720B2
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
sequence shown
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019560545A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019124468A1 (ja
Inventor
耕治 玉田
幸美 佐古田
圭志 安達
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Noile-Immune Biotech Inc
Original Assignee
Noile-Immune Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noile-Immune Biotech Inc filed Critical Noile-Immune Biotech Inc
Publication of JPWO2019124468A1 publication Critical patent/JPWO2019124468A1/ja
Priority to JP2023021295A priority Critical patent/JP7475088B2/ja
Application granted granted Critical
Publication of JP7233720B2 publication Critical patent/JP7233720B2/ja
Priority to JP2024062451A priority patent/JP7696658B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/852—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/86—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/54—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2019560545A 2017-12-24 2018-12-19 ヒトメソセリンを特異的に認識する細胞表面分子、il-7、及びccl19を発現する免疫担当細胞 Active JP7233720B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023021295A JP7475088B2 (ja) 2017-12-24 2023-02-15 ヒトメソセリンを特異的に認識する細胞表面分子、il-7、及びccl19を発現する免疫担当細胞
JP2024062451A JP7696658B2 (ja) 2017-12-24 2024-04-09 ヒトメソセリンを特異的に認識する細胞表面分子、il-7、及びccl19を発現する免疫担当細胞

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017247109 2017-12-24
JP2017247109 2017-12-24
PCT/JP2018/046888 WO2019124468A1 (ja) 2017-12-24 2018-12-19 ヒトメソセリンを特異的に認識する細胞表面分子、il-7、及びccl19を発現する免疫担当細胞

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023021295A Division JP7475088B2 (ja) 2017-12-24 2023-02-15 ヒトメソセリンを特異的に認識する細胞表面分子、il-7、及びccl19を発現する免疫担当細胞

Publications (2)

Publication Number Publication Date
JPWO2019124468A1 JPWO2019124468A1 (ja) 2021-01-21
JP7233720B2 true JP7233720B2 (ja) 2023-03-07

Family

ID=66993541

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019560545A Active JP7233720B2 (ja) 2017-12-24 2018-12-19 ヒトメソセリンを特異的に認識する細胞表面分子、il-7、及びccl19を発現する免疫担当細胞
JP2023021295A Active JP7475088B2 (ja) 2017-12-24 2023-02-15 ヒトメソセリンを特異的に認識する細胞表面分子、il-7、及びccl19を発現する免疫担当細胞
JP2024062451A Active JP7696658B2 (ja) 2017-12-24 2024-04-09 ヒトメソセリンを特異的に認識する細胞表面分子、il-7、及びccl19を発現する免疫担当細胞

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023021295A Active JP7475088B2 (ja) 2017-12-24 2023-02-15 ヒトメソセリンを特異的に認識する細胞表面分子、il-7、及びccl19を発現する免疫担当細胞
JP2024062451A Active JP7696658B2 (ja) 2017-12-24 2024-04-09 ヒトメソセリンを特異的に認識する細胞表面分子、il-7、及びccl19を発現する免疫担当細胞

Country Status (20)

Country Link
US (2) US20200323920A1 (cg-RX-API-DMAC7.html)
EP (1) EP3730612B1 (cg-RX-API-DMAC7.html)
JP (3) JP7233720B2 (cg-RX-API-DMAC7.html)
KR (1) KR102830462B1 (cg-RX-API-DMAC7.html)
CN (1) CN111511911B (cg-RX-API-DMAC7.html)
AU (1) AU2018388079B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020012848A2 (cg-RX-API-DMAC7.html)
CA (1) CA3086658A1 (cg-RX-API-DMAC7.html)
DK (1) DK3730612T3 (cg-RX-API-DMAC7.html)
EA (1) EA202091488A1 (cg-RX-API-DMAC7.html)
ES (1) ES3066520T3 (cg-RX-API-DMAC7.html)
FI (1) FI3730612T3 (cg-RX-API-DMAC7.html)
IL (1) IL275453B2 (cg-RX-API-DMAC7.html)
MX (1) MX428412B (cg-RX-API-DMAC7.html)
PL (1) PL3730612T3 (cg-RX-API-DMAC7.html)
PT (1) PT3730612T (cg-RX-API-DMAC7.html)
SA (1) SA520412282B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202005908WA (cg-RX-API-DMAC7.html)
TW (1) TWI811278B (cg-RX-API-DMAC7.html)
WO (1) WO2019124468A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202190624A1 (ru) * 2018-08-31 2021-06-09 Нойл-Иммьюн Байотек, Инк. Car-экспрессирующие т-клетки и car-экспрессирующий вектор
WO2020146902A2 (en) 2019-01-11 2020-07-16 Minerva Biotechnologies Corporation Anti-variable muc1* antibodies and uses thereof
IL292542B2 (en) * 2019-10-28 2025-11-01 Noile Immune Biotech Inc Drug for treating cancer, combination drug, drug composition, immune responsive cell, nucleic acid delivery vehicle, and product
CN111235113A (zh) * 2020-01-21 2020-06-05 南京北恒生物科技有限公司 包含嵌合抗原受体的免疫细胞及其用途
KR102309543B1 (ko) 2020-08-04 2021-10-07 주식회사 셀렌진 메소텔린에 특이적으로 결합하는 항-메소텔린 키메릭 항원 수용체
WO2022092841A1 (ko) * 2020-10-28 2022-05-05 주식회사 티에스디라이프사이언스 이종 면역세포에 대한 화학주성을 유도하는 형질전환된 면역세포
CN113380324B (zh) * 2021-05-17 2023-06-27 西安交通大学 一种T细胞受体序列motif组合识别检测方法、存储介质及设备
WO2023009700A2 (en) * 2021-07-29 2023-02-02 Takeda Pharmaceutical Company Limited Car-expressing immune cells that specifically target mesothelin and uses thereof
US20240350627A1 (en) * 2021-07-29 2024-10-24 Takeda Pharmaceutical Company Limited Engineered immune cell that specifically targets mesothelin and uses thereof
CN113651893B (zh) * 2021-08-12 2023-08-01 上海生物制品研究所有限责任公司 联合her2和meso双靶点car-t载体及其构建方法和在癌症中的应用
CN119923410A (zh) 2022-07-28 2025-05-02 莱蒂恩技术公司 用于治疗实体瘤的嵌合抗原受体治疗
US20240261406A1 (en) 2023-02-02 2024-08-08 Minerva Biotechnologies Corporation Chimeric antigen receptor compositions and methods for treating muc1* diseases
WO2025255291A1 (en) * 2024-06-07 2025-12-11 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptors targeting mesothelin and use thereof
WO2026121219A1 (ja) * 2024-12-03 2026-06-11 ノイルイミューン・バイオテック株式会社 遺伝子改変免疫担当細胞の製造方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008143684A1 (en) 2006-10-05 2008-11-27 Fred Hutchinson Cancer Research Center Methods of generation use of in vivo biotinylated recombinant antibodies
WO2010028795A1 (en) 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Multivalent antibodies
JP2011504372A (ja) 2007-11-26 2011-02-10 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 抗メソセリン抗体およびその使用
WO2013063419A2 (en) 2011-10-28 2013-05-02 The Trustees Of The University Of Pennsylvania A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
JP2013517317A (ja) 2010-01-20 2013-05-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗凝固薬の解毒剤
WO2016056228A1 (ja) 2014-10-09 2016-04-14 国立大学法人山口大学 Car発現ベクター及びcar発現t細胞
WO2017159736A1 (ja) 2016-03-17 2017-09-21 国立大学法人山口大学 免疫機能制御因子を発現する免疫担当細胞及び発現ベクター
WO2017177149A2 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2928287B2 (ja) 1988-09-29 1999-08-03 協和醗酵工業株式会社 新規ポリペプチド
EP2257572A1 (en) 2008-03-27 2010-12-08 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Human anti-mesothelin monoclonal antibodies
JP5934099B2 (ja) * 2009-10-01 2016-06-15 アメリカ合衆国 抗血管内皮増殖因子受容体−2キメラ抗原受容体及び癌の治療のためのその使用
WO2015188141A2 (en) 2014-06-06 2015-12-10 Memorial Sloan-Kettering Cancer Ceneter Mesothelin-targeted chimeric antigen receptors and uses thereof
CA3075886A1 (en) * 2017-10-10 2019-04-18 Yamaguchi University Enhancer for t-cells or b-cells having memory function, malignant tumor recurrence inhibitor, and inducer for inducing memory function in t-cells or b-cells

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008143684A1 (en) 2006-10-05 2008-11-27 Fred Hutchinson Cancer Research Center Methods of generation use of in vivo biotinylated recombinant antibodies
JP2011504372A (ja) 2007-11-26 2011-02-10 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 抗メソセリン抗体およびその使用
WO2010028795A1 (en) 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Multivalent antibodies
JP2013517317A (ja) 2010-01-20 2013-05-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗凝固薬の解毒剤
WO2013063419A2 (en) 2011-10-28 2013-05-02 The Trustees Of The University Of Pennsylvania A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
WO2016056228A1 (ja) 2014-10-09 2016-04-14 国立大学法人山口大学 Car発現ベクター及びcar発現t細胞
WO2017159736A1 (ja) 2016-03-17 2017-09-21 国立大学法人山口大学 免疫機能制御因子を発現する免疫担当細胞及び発現ベクター
WO2017177149A2 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy

Also Published As

Publication number Publication date
CA3086658A1 (en) 2019-06-27
CN111511911A (zh) 2020-08-07
TW201930589A (zh) 2019-08-01
JP7475088B2 (ja) 2024-04-26
BR112020012848A2 (pt) 2021-01-26
IL275453A (en) 2020-08-31
EP3730612A4 (en) 2021-09-01
JP7696658B2 (ja) 2025-06-23
PL3730612T3 (pl) 2026-06-08
JPWO2019124468A1 (ja) 2021-01-21
IL275453B2 (en) 2024-06-01
AU2018388079B2 (en) 2024-11-14
KR20200103708A (ko) 2020-09-02
DK3730612T3 (da) 2026-05-04
FI3730612T3 (fi) 2026-04-30
EP3730612B1 (en) 2026-02-04
IL275453B1 (en) 2024-02-01
SG11202005908WA (en) 2020-07-29
AU2018388079A1 (en) 2020-07-16
PT3730612T (pt) 2026-03-30
SA520412282B1 (ar) 2023-11-09
MX2020006666A (es) 2020-08-31
US20200323920A1 (en) 2020-10-15
TWI811278B (zh) 2023-08-11
JP2023053328A (ja) 2023-04-12
ES3066520T3 (en) 2026-05-13
KR102830462B1 (ko) 2025-07-04
EP3730612A1 (en) 2020-10-28
EA202091488A1 (ru) 2020-09-23
WO2019124468A1 (ja) 2019-06-27
JP2024086826A (ja) 2024-06-28
US20240139248A1 (en) 2024-05-02
CN111511911B (zh) 2023-11-03
MX428412B (es) 2025-11-13

Similar Documents

Publication Publication Date Title
JP7475088B2 (ja) ヒトメソセリンを特異的に認識する細胞表面分子、il-7、及びccl19を発現する免疫担当細胞
JP7527049B2 (ja) Car発現ベクター及びcar発現t細胞
JP2021121198A (ja) 免疫機能制御因子を発現する免疫担当細胞
CN115885038A (zh) 表达嵌合抗原受体的免疫活性细胞
US20260053856A1 (en) Immunocompetent cell and expression vector expressing regulatory factors of immune function / a cell surface molecule specifically recognizing human mesothelin, il-7 and ccl19
EA042661B1 (ru) Иммунокомпетентная клетка, которая экспрессирует молекулу клеточной поверхности, специфически распознающую человеческий мезотелин, il-7 и ccl19
HK40030365A (en) Immunocompetent cell that expresses a cell surface molecule specifically recognizing human mesothelin, il-7 and ccl19
HK40030365B (en) Immunocompetent cell that expresses a cell surface molecule specifically recognizing human mesothelin, il-7 and ccl19

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221223

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230116

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230215

R150 Certificate of patent or registration of utility model

Ref document number: 7233720

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250